Pannextherapeutics
1 known investors
Pannex Therapeutics is developing Pannexin 1 (Panx1) channel blockers, a drug platform targeting pathological ATP release that drives neuroinflammation and immune dysregulation. Its therapeutics address unmet medical needs in neurology and oncology.
Founders & leadership
DB
David BravoChief Executive Officer & Co-founder
TG
Thomas GerlachChief Strategic Officer & Co-founder
GG
Gerhard GrossChief Scientific Officer & Co-founder
Investors · 1
Frequently asked questions
- What does Pannextherapeutics do?
- Pannex Therapeutics is developing Pannexin 1 (Panx1) channel blockers, a drug platform targeting pathological ATP release that drives neuroinflammation and immune dysregulation. Its therapeutics address unmet medical needs in neurology and oncology.
- Who founded Pannextherapeutics?
- Pannextherapeutics was founded by David Bravo, Thomas Gerlach, Gerhard Gross.
- Who are Pannextherapeutics's investors?
- Pannextherapeutics's investors include Ganesha Lab.